Improvement of glycemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicenter, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).

Yuka TakahashiHiroshi NomotoHiroki YokoyamaYoshinari TakanoSo NagaiAtsushi TsuzukiKyu Yong ChoAika MiyaHiraku KamedaJun TakeuchiShinji TanedaYoshio KuriharaTatsuya AtsumiAkinobu NakamuraHideaki Miyoshinull null

Published in: Diabetes, obesity & metabolism (2023)

Once-weekly semaglutide administration improved glycemic control and treatment satisfaction after switching from liraglutide or dulaglutide. These results highlighted a useful treatment option for patients with metabolic abnormalities despite GLP-1 receptor agonist treatment. This article is protected by copyright. All rights reserved.

Keyphrases

glycemic control
open label
type diabetes
randomized controlled trial
blood glucose
replacement therapy
phase iii
phase ii
study protocol
rectal cancer
locally advanced